Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-11-26FDA Approved: TOUJEO — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for TOUJEO (insulin glargine) from Sanofi-Aventis U.S. LLC.
-
CLINICAL_TRIALS trial_result · 2019-11-26Clinical Trial Update: Randomized Trial Comparing Colesevelam vs. Ezetimibe [Phase 4]
A Phase 4 randomized trial comparing colesevelam versus ezetimibe in adults with type 2 diabetes mellitus has completed.
-
FDA approval · 2019-11-25FDA Approved: METFORMIN HYDROCHLORIDE — Original Application (GLENMARK PHARMACEUTICALS INC., USA)
FDA approved Metformin hydrochloride from Glenmark as an original generic application.
-
CLINICAL_TRIALS trial_result · 2019-11-20Clinical Trial Update: Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy [Phase 3]
Phase 3 trial evaluating the effects of canagliflozin on renal and cardiovascular outcomes in patients with type 2 diabetes and diabetic nep…
-
CLINICAL_TRIALS trial_result · 2019-11-19Clinical Trial Update: A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. [Phase 2]
A Phase 2 trial evaluating different doses of 0382 in overweight and obese adults with Type 2 Diabetes Mellitus has completed with results p…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-11-18Clinical Trial Update: A Phase 2 Study of Cyclo-Z in Subjects With Type 2 Diabetes [Phase 2]
Phase 2 clinical trial of Cyclo-Z in adults with Type 2 diabetes has completed.
-
CLINICAL_TRIALS trial_result · 2019-11-18Clinical Trial Update: Autologous Adult Stem Cells to Patients With Type 1 Diabetes and a Successful Renal Transplant [Phase 1]
Phase 1 trial update evaluating autologous adult stem cells in patients with Type 1 diabetes and successful renal transplant; results posted…
-
CLINICAL_TRIALS research · 2019-11-18Clinical Trial Update: Impact of Hypoglycaemia in Patients With Diabetes Mellitus Type 2 on Platelet Activation [NA]
Clinical trial update examining the impact of hypoglycemia on platelet activation in patients with type 2 diabetes mellitus.
-
FDA approval · 2019-11-15FDA Approved: HUMULIN 70/30 — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for HUMULIN 70/30 (insulin human) submitted by Eli Lilly and Company.
-
FDA approval · 2019-11-15FDA Approved: HUMULIN N — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for HUMULIN N (insulin human) from Eli Lilly and Company.
-
FDA approval · 2019-11-15FDA Approved: HUMALOG MIX75/25 — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for Humalog Mix75/25 (insulin lispro) from Eli Lilly and Company.
-
FDA approval · 2019-11-15FDA Approved: HUMALOG MIX50/50 KWIKPEN — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for HUMALOG MIX50/50 KWIKPEN (insulin lispro) from Eli Lilly.
-
FDA approval · 2019-11-15FDA Approved: NOVOLIN N — Supplemental Application (Novo Nordisk)
FDA approved a supplemental application for NOVOLIN N (human insulin) from Novo Nordisk.
-
FDA approval · 2019-11-15FDA Approved: HUMALOG KWIKPEN — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for Humalog KwikPen (insulin lispro) from Eli Lilly and Company.
-
FDA approval · 2019-11-15FDA Approved: BASAGLAR KWIKPEN — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for BASAGLAR KWIKPEN (insulin glargine) from Eli Lilly and Company.
-
FDA approval · 2019-11-15FDA Approved: SOLIQUA 100/33 — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for SOLIQUA 100/33 (insulin glargine and lixisenatide) from Sanofi-Aventis U.S. LLC.
-
FDA approval · 2019-11-15FDA Approved: FIASP — Supplemental Application (Novo Nordisk)
The FDA approved a supplemental application for FIASP (insulin aspart injection) from Novo Nordisk.
-
FDA approval · 2019-11-15FDA Approved: LEVEMIR — Supplemental Application (Novo Nordisk)
The FDA approved a supplemental application for LEVEMIR (insulin detemir) by Novo Nordisk, resulting in updated labeling for the product.
-
FDA approval · 2019-11-15FDA Approved: INSULIN LISPRO — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for insulin lispro from Eli Lilly, updating/expanding its approved use.
-
FDA approval · 2019-11-15FDA Approved: INSULIN ASPART PROTAMINE AND INSULIN ASPART MIX 70/30 — Supplemental Application (Novo Nordisk Pharma, Inc.)
FDA approved a supplemental application for Insulin Aspart Protamine and Insulin Aspart Mix 70/30 from Novo Nordisk Pharma, Inc.
-
FDA approval · 2019-11-15FDA Approved: HUMULIN R — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for Humulin R (insulin human) submitted by Eli Lilly and Company.
-
FDA approval · 2019-11-15FDA Approved: TOUJEO — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental application for Toujeo (insulin glargine) from Sanofi-Aventis U.S. LLC.
-
FDA approval · 2019-11-15FDA Approved: XULTOPHY 100/3.6 — Supplemental Application (Novo Nordisk)
FDA approved a supplemental application for XULTOPHY 100/3.6, a fixed-ratio combination of insulin degludec and liraglutide, from Novo Nordi…
-
FDA approval · 2019-11-15FDA Approved: ADMELOG — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental application for ADMELOG (insulin lispro) submitted by Sanofi-Aventis U.S. LLC.
-
CLINICAL_TRIALS trial_result · 2019-11-15Clinical Trial Update: Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001) [Phase 1]
Phase 1 single ascending dose study of MK-1092 in healthy participants and in individuals with Type 1 and Type 2 diabetes completed with res…